News

Jerusalem, Israel, January 4, 2010 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) will host a live audio webcast at the Goldman Sachs Healthcare CEOs Unscripted Conference in New York. William Marth, President and CEO, Teva North America, will present on Wednesday, January 6, 2010. What: Teva Presentation at the Goldman Sachs Healthcare CEOs Unscripted Conference in New York. Who: William Marth, President and CEO, Teva North America When: Wednesday, January 6, 2010 at 2:45 p.m. ET Where: http://cc.talkpoint.com/gold006/010610a_mg/?entity=1_C85FKGI or http://www.tevapharm.com/financial/ H Read More »

Jerusalem, Israel, January 7, 2010 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that it has entered into two definitive agreements with AstraZeneca to settle patent litigation regarding Teva's U.S. generic versions of AstraZeneca's Prilosec® (omeprazole) and Nexium® (esomeprazole), including all claims for patent infringement and damages.Under the terms of the omeprazole agreement, Teva will obtain a release for all past sales of its generic omeprazole and will continue to market its product in the U.S. and will make a one-time payment to AstraZeneca. As part of the eso Read More »

-- Sets Goals of $31 Billion in Revenues and Non-GAAP Net Income of $6.8 Billion by 2015 --Jerusalem, Israel, January 7, 2010 - During its investor meeting today, Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) presented an updated strategy, highlighting key opportunities for growth and announcing its long-term goals of reaching revenues of $31 billion and non-GAAP net income of $6.8 billion, or 22% of revenues, by 2015. "In the years to come, Teva will seek to extend our global leadership and deliver profitable growth, doubling our revenues by 2015 and reaching net income margins of 2 Read More »

Jerusalem, Israel, January 8, 2010 - Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) will host a live audio webcast at the 28th Annual J.P. Morgan Healthcare Conference in San Francisco, CA. Eyal Desheh, Chief Financial Officer and William Marth, President and CEO, Teva North America, will present on Monday, January 11, 2010. What: Teva Presentation at the 28th Annual J.P. Morgan Healthcare Conference in San Francisco, CA.Who: Eyal Desheh, Chief Financial OfficerWilliam Marth, President and CEO, Teva North America When: Monday, January 11, 2010 at 1:30 p.m. (PST)Where: www.tevapharm.com or Read More »

Jerusalem, Israel, January 14, 2010 - Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) announced today that Moody's Investor services has upgraded the Company's rating to A3 from Baa1. Following this most recent upgrade, the rating outlook is now stable. Teva is the first generics-focused pharmaceutical company to be rated in Moody's "A" category. In its statement, Moody's indicated that the upgrade of Teva reflects a favorable growth outlook, clearly articulated financial targets and the expectation that M&A can be financed with debt levels appropriate for the A3 rating. The A Read More »

Jerusalem, Israel, January 19, 2010 - Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) announced today that it will release its fourth quarter and full year 2009 financial results on Tuesday, February 16, 2010. Teva will host a conference call and live webcast on the same day, at 8:30 a.m. ET to discuss its fourth quarter and full year 2009 results and overall business environment. A Question & Answer session will follow this discussion. The earnings release will be available on Teva's web site at www.tevapharm.com prior to the call.Investors and other interested parties may access a liv Read More »

Jerusalem, Israel, January 19, 2010 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that it will be donating over $7 million in medicine to benefit earthquake victims in Haiti. Teva is working with several of its Non-Governmental Organization (NGO) partners to ensure these drugs are delivered to Haiti without delay."All of us at Teva were devastated to hear about the earthquake and our hearts and thoughts go out to the country of Haiti," said Shlomo Yanai, President and Chief Executive Officer of Teva Pharmaceutical Industries Ltd. "Working with our partners Read More »

Jerusalem, Israel, January 21, 2010 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. Food and Drug Administration (FDA) has granted tentative approval for the Company's Abbreviated New Drug Application (ANDA) to market its generic version of Novartis' breast cancer treatment Femara® (letrozole) Tablets, 2.5 mg. Final approval of Teva's Letrozole Tablets is expected upon expiry of patent protection for the brand product in June 2011.The brand product had annual sales of approximately $556 million in the United States, based on IMS sales data.About TevaTeva Phar Read More »

Jerusalem, Israel, January 22, 2010 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. Court of Appeals for the Federal Circuit has affirmed a Nov. 10, 2009, District Court decision that the Company's generic version of Takeda's Prevacid® (lansoprazole) SoluTab does not infringe U.S. Patent No. 5,464,632.Teva's Abbreviated New Drug Application (ANDA) to market lansoprazole orally disintegrating tablets is currently pending final approval at the U.S. Food and Drug Administration (FDA).Annual sales of the brand product were approximately $513 million in the United Read More »

Jerusalem, Israel, January 26, 2010 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. District Court for the District of Delaware has issued a decision in its litigation over the Company's Abbreviated New Drug Application (ANDA) to market its generic version of Schering-Plough's brain tumor treatment Temodar® (temozolomide). The Court found that U.S. Patent No. 5,260,291 is not enforceable due to prosecution laches and inequitable conduct.Teva's tentatively approved ANDA to market temozolomide is currently pending final approval at the U.S. Food and Drug Admini Read More »